ABVX · NASDAQ · STOCK
Abivax (ABVX) Stock Analysis
$88.14
52W $69.81 – $148.83
52/100
$6.47B
-16.8
-0.25
Is ABVX Bullish or Bearish?
Mixed.
Innellis AI committee rates Abivax S.A. (ABVX) Watch with a composite score of 52/100
, based on 6 analysts with 67% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +8.25 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -11.75 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 19.9x prices in significant intangible value — Value
- ROE of only -107.8% -- cheap may mean cheap for a reason — Value
- 4 consecutive earnings misses -- execution concerns — Growth
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
- Daily trend (downtrend) conflicts with the weekly trend (uptrend) -- fighting the larger trend — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
52/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 88%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 19.9x prices in significant intangible value
Growth Analyst
neutral
52
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− 4 consecutive earnings misses -- execution concerns
Technical Analyst
bearish
39
/ 100 · High confidence
Price action is deteriorating -- trend and/or momentum are working against this name
− Price structure making lower highs and lower lows
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 30.2% signals elevated volatility
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
53
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 51.8 to 51.8.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Risk Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
30.3
Neutral
MACD Histogram
-0.375
Bearish Momentum
Trend Direction
Downtrend
Weekly: Uptrend
Market Structure
Mixed
Support
$69.91
Resistance
$92.73
Bollinger %B
0.19
Inside Bands
Price vs Moving Averages
EMA 9
$91.41
Below
EMA 21
$97.46
Below
EMA 50
$106.43
Below
EMA 200
$108.11
Below
Fundamental Analysis
Valuation
67
Growth
25
Profitability
50
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-16.8×
P/B Ratio
17.18×
PEG Ratio
0.30
Dividend Yield
0.00%
52W High
$148.83
52W Low
$69.81
Quality & Growth
ROE
-7386.7%
ROA
-5754.3%
Gross Margin
—
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -16.8 (inexpensive relative to a 15-40x range); Price-to-book of 17.2x; PEG ratio of 0.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -73.9%; Return on assets of -57.5%; Net margin of 17488.9%; Gross margin of 153.1%; Current ratio of 5.97 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-1.85); Most recent quarter missed estimates by 14.5%; 4 consecutive earnings misses; EPS growth accelerating (-103.8% -> +35.5% QoQ); Average YoY EPS growth of -56.9%; Analyst estimates falling over recent quarters
Get the Full ABVX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →